Jean-Charles Soria/LinkedIn
Mar 8, 2025, 02:12
Jean-Charles Soria: The oncology dealmaking landscape is shifting
Jean-Charles Soria, Head of Oncology Therapeutic Area at Amgen, posted on LinkedIn
“The oncology dealmaking landscape is shifting! Pharma is moving beyond niche drugs to focus on ADCs, bispecifics and radioligand therapies. Low interest in narrow biomarker drugs, pharma is chasing pan-cancer blockbusters!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:48
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53